the reimbursement institutions in Turkey has been reflected upon the costs. As a value of effectiveness, the rate of completing the treatment has been chosen. The success rate of completing the treatment determined as 2 doses and 3 doses per day has been gathered from the literature. The completion level of the treatment for 2 doses per day is 68% and for the agents used for 3 doses, it is 50%. RESULTS: In terms of incremental cost per additional completing doses, amoxicillin clavulanate is cost saving versus amoxicillin group for the treatment of community acquired pneumonia , acute rhinosinusitis , acute otitis media , tonsillopharyngitis . CONCLUSIONS: According to the results derived from the comparison between the costs and effectiveness values; for the each illness at primary care, the use of amoxicillin clavulanate is cost saving in order to complete the treatment successfully. OBJECTIVES: HPV vaccination of young girls is a preventive strategy now recommended in most industrialised countries. As HPV can cause cancers and diseases in both sexes, questions are raised about the health and economic impact of extending HPV vaccination programme to boys. The aim of this study was to review the cost-effectiveness studies of boys HPV vaccination and provide recommendations for future research. METHODS: Cost-effectiveness models of HPV vaccination that consider boys vaccination as a possible vaccination strategy published before the end of 2011 were included in the study. Models were compared from a number of aspects, including modelling approach, model calibration, diseases modelled, HPV transmission patterns, vaccination and screening strategies and input parameters (transition probabilities, costs, effectiveness, discount rates). RESULTS: Six US and three European studies were included in the review. Four in nine used a standard dynamic model, and three different types of models were used in other studies. Results differed widely according to HPV-related diseases considered: analyses modelling cervical cancer only, with or without genital warts, yielded a higher cost-effectiveness ratio. The comparator considered usually did not account for vaccination strategies implemented. Results were very sensitive to country-specific parameters, such as the current vaccination coverage in girls (the most favourable cost-effectiveness ratios for boy vaccination were achieved when girls vaccination coverage was low), vaccine price, vaccine characteristics and the assumption on natural immunity of HPV. CONCLUSIONS: Few analyses examined the cost-effectiveness of extending HPV vaccination to boys. As methods and parameters differed across studies, the review provided limited conclusions. The cost-effectiveness of a girls and boys vaccination programme should include all benefits expected from HPV vaccination and should be evaluated on a country-bycountry basis to take into account local specificities, such as observed coverage rate in girls and vaccine price. OBJECTIVES: Chronic hepatitis C genotype 1 (HCV) may lead to cirrhosis, liver cancer, liver transplant, increased mortality. Peginterferon-alpha and ribavirin (PR) results in complete cure (Sustained Viral Response) in less than 50% of patients. Aim of this study was to assess the cost-utility of telaprevirϩPR (TPR) compared to boceprevirϩPR (BPR) and PR alone in the management of HCV in adults with mild, moderate HCV, compensated liver disease, including cirrhosis, who have not been treated before or have been treated with PR but failed treatment. METHODS: A Markov model with a lifelong time horizon using annual cycles was developed to compare TPR, BPR and PR in treatment-naïve patients (TN) and treatment-experienced patients (TE). Clinical data were provided by published phase 3 trials (TPR vs. PR, BPR vs. PR) and a mixed treatment comparison for the indirect comparison TPR vs. BPR. Dutch unit costs (direct and indirect) and utilities were taken from a Dutch observational study in HCV patients. Annual discounting of 4% and 1.5% was applied on costs and outcomes respectively. The cost per quality-adjusted life-year (QALY) was calculated from the societal perspective using the Human Capital Approach. RESULTS: Treating TN with TPR generates 0.85 QALYs gained and €634 additional cost compared to PR, resulting in an incremental cost-utility ratio (ICUR) of €746/QALY. In TE, TPR dominates PR with cost-savings (-€6,621) and 1.78 additional QALYs. Also, TPR dominates BPR with higher effects (0.20 in TN; 0.79 in TE) and cost-savings (-€7,224 in TN; -€22,110 in TE). Sensitivity analysis showed that time horizon affected the ICERs. The probability to obtain an ICERϽ20,000€/QALY is 100% (probabilistic sensitivity analysis). CONCLUSIONS: Based on the results of this local adaptation, TPR is highly cost effective versus PR alone in TN patients. It was a dominant option in all other comparisons (including boceprevir and treatment for TE patients). 
OBJECTIVES: HPV vaccination of young girls is a preventive strategy now recommended in most industrialised countries. As HPV can cause cancers and diseases in both sexes, questions are raised about the health and economic impact of extending HPV vaccination programme to boys. The aim of this study was to review the cost-effectiveness studies of boys HPV vaccination and provide recommendations for future research. METHODS: Cost-effectiveness models of HPV vaccination that consider boys vaccination as a possible vaccination strategy published before the end of 2011 were included in the study. Models were compared from a number of aspects, including modelling approach, model calibration, diseases modelled, HPV transmission patterns, vaccination and screening strategies and input parameters (transition probabilities, costs, effectiveness, discount rates). RESULTS: Six US and three European studies were included in the review. Four in nine used a standard dynamic model, and three different types of models were used in other studies. Results differed widely according to HPV-related diseases considered: analyses modelling cervical cancer only, with or without genital warts, yielded a higher cost-effectiveness ratio. The comparator considered usually did not account for vaccination strategies implemented. Results were very sensitive to country-specific parameters, such as the current vaccination coverage in girls (the most favourable cost-effectiveness ratios for boy vaccination were achieved when girls vaccination coverage was low), vaccine price, vaccine characteristics and the assumption on natural immunity of HPV. CONCLUSIONS: Few analyses examined the cost-effectiveness of extending HPV vaccination to boys. As methods and parameters differed across studies, the review provided limited conclusions. The cost-effectiveness of a girls and boys vaccination programme should include all benefits expected from HPV vaccination and should be evaluated on a country-bycountry basis to take into account local specificities, such as observed coverage rate in girls and vaccine price. 
PIN61 THE COST-UTILITY OF TELAPREVIR IN COMBINATION WITH PEGINTERFEON ALPHA AND RIBAVIRIN (PR) AS COMPARED TO THE COMBINATION BOCEPREVIR WITH PR AND TO PR ALONE IN THE MANAGEMENT OF CHRONIC HEPATITIS C IN THE NETHERLANDS

OBJECTIVES:
Chronic hepatitis C genotype 1 (HCV) may lead to cirrhosis, liver cancer, liver transplant, increased mortality. Peginterferon-alpha and ribavirin (PR) results in complete cure (Sustained Viral Response) in less than 50% of patients. Aim of this study was to assess the cost-utility of telaprevirϩPR (TPR) compared to boceprevirϩPR (BPR) and PR alone in the management of HCV in adults with mild, moderate HCV, compensated liver disease, including cirrhosis, who have not been treated before or have been treated with PR but failed treatment. METHODS: A Markov model with a lifelong time horizon using annual cycles was developed to compare TPR, BPR and PR in treatment-naïve patients (TN) and treatment-experienced patients (TE). Clinical data were provided by published phase 3 trials (TPR vs. PR, BPR vs. PR) and a mixed treatment comparison for the indirect comparison TPR vs. BPR. Dutch unit costs (direct and indirect) and utilities were taken from a Dutch observational study in HCV patients. Annual discounting of 4% and 1.5% was applied on costs and outcomes respectively. The cost per quality-adjusted life-year (QALY) was calculated from the societal perspective using the Human Capital Approach. RESULTS: Treating TN with TPR generates 0.85 QALYs gained and €634 additional cost compared to PR, resulting in an incremental cost-utility ratio (ICUR) of €746/QALY. In TE, TPR dominates PR with cost-savings (-€6,621) and 1.78 additional QALYs. Also, TPR dominates BPR with higher effects (0.20 in TN; 0.79 in TE) and cost-savings (-€7,224 in TN; -€22,110 in TE). Sensitivity analysis showed that time horizon affected the ICERs. The probability to obtain an ICERϽ20,000€/QALY is 100% (probabilistic sensitivity analysis). CONCLUSIONS: Based on the results of this local adaptation, TPR is highly cost effective versus PR alone in TN patients. It was a dominant option in all other comparisons (including boceprevir and treatment for TE patients). OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C in Germany (62% genotype 1). Treatment of genotype 1 chronic Hepatitis C has been improved by recently approved new direct acting antivirals. Clinical studies showed a significant increase in sustained virological response rates from 38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced triple therapy with Telaprevir (TVRϩPR) compared to dual therapy (PR) for the treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated patients. METHODS: A previously published economic Markov model comparing triple therapy (TVRϩPR) and dual therapy (PR) was adjusted for the German health care context (payer perspective). Effectiveness was measured on the basis of quality adjusted life years (QALY). Clinical outcomes and drug dosage were taken from the ADVANCE phase-3 trial. Other model parameters -including utilities -were adapted from German or if not available from international literature after an extensive literature search. Drug costs were taken from the German drug directory. All costs were inflated to the year 2012. A discount rate of 3% and a lifetime horizon were assumed. RESULTS: Base-case analysis shows that triple treatment (TVRϩPR) compared with dual therapy (PR) results in higher costs (€49,378 vs. €30,743) and better outcomes (16.7 vs. 15.8 QALYs). The incremental costs per QALY gained were €21,277. Results were robust in multiple sensitivity analyses. Discount rate seemed to have major impact: a discount rate of 0% results in an ICER of 7,381 €/QALY, a discount rate of 5% in 34,694 €/QALY. CE acceptability curve shows a probability of an ICER below 30,000 €/QALY of more than 90%. CONCLUSIONS: Triple therapy with telaprevir for treatment-naïve HCV-genotype 1 patients is more effective than dual therapy, but results in higher costs (notably drug costs). 
PIN62 COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAÏVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY
PIN63 VACCINATION AGAINST HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE: A COST-EFFECTIVENESS ANALYSIS
OBJECTIVES:
Herpes Zoster (HZ) is a painful disease resulting from reactivation of the varicella-zoster virus which can cause post-herpetic neuralgia (PHN), a debilitating pain persisting from three months to years after rash onset. The incidence and severity associated with HZ negatively impacts functional status and quality of life and increases with advancing age. A vaccine preventing HZ and PHN in people aged 50 and more will soon be available in Europe. This study aimed to assess the cost-effectiveness of zoster vaccination in France. METHODS: A published Markov model was adapted to the French setting. Cost-effectiveness of vaccinating 20% of individuals aged 70-79 was evaluated over lifetime from a national health care perspective. Base case analysis considered French epidemiological, economic and EQ-5D based utility data. The analysis assumed a waning vaccine efficacy of 4.15% annually as suggested by clinical data. A discount of 4% was applied to costs and outcomes over the first 30 years and a 2% rate thereafter. Extensive sensitivity analyses were performed on factors of influence described in the literature. RESULTS: Incremental cost-effectiveness ratios were estimated at 9,693€ per QALY gained, 1,529€ per avoided HZ case and 3,480€ per avoided PHN case. The probability that the ICERs were below €28,000 to €84,000/QALY (one to three times the GDP per capita) were greater than 92% and 95%, respectively. Univariate sensitivity analysis confirmed the favorable cost-effectiveness profile, ranging from 5,793 to 19,565€/QALY gained. Duration of protection and utility estimates were the most impactful parameters. Vaccination policy targeting other cohorts, such as people aged 65 years-old was also found cost-effective, with an ICER estimated at 7,217€/ QALY gained. CONCLUSIONS: Beyond epidemiological and clinical evidence, health-economic evidence supports the implementation of a zoster vaccination policy in the French senior population aged 70 and over. OBJECTIVES: Streptococcus pneumoniaeis a leading cause of life-threatening pneumococcal disease. In the UK, PPV23 is recommended in the elderly (aged 65 and over) and at-risk adults. In 2007, PCV was introduced in children, leading to a decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV serotypes not only in vaccinated children but also in unvaccinated adults. The use of PCV13 in adults is currently under consideration pending data on efficacy in this population. This study assessed the CE of PPV23 vs. PCV13 or NoVac in the UK, accounting for epidemiological changes. METHODS: An existing population-based Markov model was adapted to the UK. Five health states were considered: no IPD, IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis sequelae and death. Epidemiology and costs were estimated from UK sources. The analysis tracked one cohort of individuals assuming PPV23, PCV13 or NoVac from 2012 until death. Costs and QALYs were discounted at 3.5%. RESULTS: Over lifetime, vaccinating the cohort with PPV23 avoided 226 (vs. PCV13) to 337 (vs. NoVac) IPD cases. Vaccinating with PPV23 resulted in an increment of 337 (vs. PCV13) to 631 (vs. NoVac) QALYs. PPV23 was associated with savings of approximately £21 million vs.
PIN64 ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UK
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